Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.2882
-0.0283 (-8.94%)
At close: May 13, 2026, 4:00 PM EDT
0.2666
-0.0216 (-7.49%)
After-hours: May 13, 2026, 7:59 PM EDT
Ensysce Biosciences Revenue
In the year 2025, Ensysce Biosciences had annual revenue of $5.07M, down -2.75%. Ensysce Biosciences had revenue of $1.88M in the quarter ending December 31, 2025, with 44.39% growth.
Revenue (ttm)
$5.07M
Revenue Growth
-2.75%
P/S Ratio
0.53
Revenue / Employee
$506,665
Employees
10
Market Cap
2.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.07M | -143.38K | -2.75% |
| Dec 31, 2024 | 5.21M | 2.98M | 133.58% |
| Dec 31, 2023 | 2.23M | -292.86K | -11.61% |
| Dec 31, 2022 | 2.52M | -1.01M | -28.54% |
| Dec 31, 2021 | 3.53M | -400.01K | -10.18% |
| Dec 31, 2020 | 3.93M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SciSparc | 856.00K |
| VivoSim Labs | 142.00K |
| Azitra | 7.50K |
| Virax Biolabs Group | 2.99K |
| Soligenix | 2.34K |
ENSC News
- 1 day ago - Ensysce announces expansion of patent protection for MPAR technology - TheFly
- 1 day ago - Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology - Accesswire
- 5 days ago - Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam - Accesswire
- 27 days ago - Ensysce secures IRB approval of final phase of PF614-MPAR-102 study - TheFly
- 27 days ago - Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study - Accesswire
- 4 weeks ago - Ensysce Biosciences files to sell 20.34M shares of common stock for holders - TheFly
- 5 weeks ago - Ensysce Biosciences secures second financing from 2025 agreement - TheFly
- 5 weeks ago - Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs - Accesswire